logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease : comparison between Belgium and the United States of a projected risk model.

    Article, Communication - En anglais

    Congress of the European Atherosclerosis Society. Brugge, BEL, 1997/05/07.

    Methodological differences and variations in health care regulations among countries often preclude direct comparisons of cost-effectiveness studies.

    A projected risk model was applied, designed to determine the economic value in the United States of pravastatin in the secondary prevention of coronary heart disease (CHD), to Belgium using local health care costs.

    A Markov process was used to model the effectiveness of treatment for 3 years with pravastatin versus placebo in 1000 male CHD patients aged 60 years and clinically similar to those in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) and pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II) studies.

    The PLAC I and II trials have shown that pravastatin treatment for 3 years at a weighted mean dose of 36.64 mg daily significantly reduced the incidence of non-fatal myocardial infarction in patients with CHD.

    Framingham data were used to project the risk of mortality 10 years post-myocardial infarction.

    The incremental cost per life year gained (LYG), after discounting costs and benefits by 5% annually, in the setting of Belgian health care regulations, was Belgian francs (BEF) 720 794 (US$ 24 359) for CHD patients with one additional risk factor ; BEF 526464 (US$ 17 792) for those with two additional risk factors ; and BEF 392 765 (US$ 13 274) for those with three or more additional risk factors. (...)

    Mots-clés Pascal : Cardiopathie coronaire, Pravastatine, Hydroxymethylglutaryl-CoA synthase, Oxo-acid-lyases, Carbon-carbon lyases, Lyases, Enzyme, Inhibiteur enzyme, Analyse coût efficacité, Economie santé, Belgique, Europe, Etats Unis, Amérique du Nord, Amérique, Etude comparative, Traitement, Prévention, Secondaire, Homme, Chimiothérapie, Hypolipémiant, Appareil circulatoire pathologie

    Mots-clés Pascal anglais : Coronary heart disease, Pravastatin, Hydroxymethylglutaryl-CoA synthase, Oxo-acid-lyases, Carbon-carbon lyases, Lyases, Enzyme, Enzyme inhibitor, Cost efficiency analysis, Health economy, Belgium, Europe, United States, North America, America, Comparative study, Treatment, Prevention, Secondary, Human, Chemotherapy, Antilipemic agent, Cardiovascular disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0406411

    Code Inist : 002B02N. Création : 25/01/1999.